Damora Therapeutics, Inc. (DMRA)
Nasdaq: DMRA · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2020
Who runs Damora Therapeutics, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Jarrett Jennifer
Director, President and CEO. First filing Mar 2026, latest Sep 28, 2026, 1 filing in all.
Officers reporting now
7
of 16 people with a filing in the last fifteen months
Directors reporting now
9
35 people on the record since 2020
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Jarrett Jennifer | Director, President and CEO | Mar 2026 | Sep 28, 2026 | none |
| Winslow Garrett | General Counsel | May 2021 | Jul 7, 2026 | 2 · $0.00 |
| Burkavage Brian | SVP, Finance | May 2026 | May 8, 2026 | none |
| Sattarzadeh Sherwin | Chief Operating Officer | Jan 2026 | Jan 26, 2026 | none |
| Hewes L. Becker | Chief Medical Officer | Jan 2026 | Jan 7, 2026 | none |
| Schambye Hans T. | Chief Executive Officer | Oct 2020 | Jan 6, 2026 | 1 · $0.00 |
| Firmani Lori | Chief Financial Officer | Aug 2024 | Jan 6, 2026 | 1 · $0.00 |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Cheng Andrew | director | Aug 2026 | Aug 13, 2026 | none |
| Bruno Julianne | director | Nov 2025 | Mar 25, 2026 | none |
| Cain Christopher W. | director | Nov 2025 | Mar 25, 2026 | none |
| Fairmount Funds Management LLC | director | Nov 2025 | Mar 25, 2026 | none |
| Fairmount Healthcare Co-Invest V L.P. | director | Nov 2025 | Mar 25, 2026 | none |
| Fairmount Healthcare Fund II L.P. | director | Nov 2025 | Mar 25, 2026 | none |
| Harwin Peter Evan | director | Nov 2025 | Mar 25, 2026 | none |
| Landsittel Michael | director | Mar 2026 | Mar 25, 2026 | none |
| Turtle Cameron | director | Mar 2026 | Mar 25, 2026 | none |
Owners of more than 10% of a classsales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Kiselak Tomas | 10% owner | Nov 2025 | Mar 25, 2026 | none |
Earlier names on the record20, newest filing first
Dallas Jayson Donald Alexander · director · last filing Jun 2025Goldfischer Carl · director · last filing Jun 2025Munshi Amit · director · last filing Jun 2025Prener Anne · director · last filing Jun 2025Shapiro David · director · last filing Jun 2025Wechsler Amy B · director · last filing Jun 2025Kronmiller Matthew · officer · last filing Jan 2025Freve Jonathan · officer · last filing Jan 2024Orbimed Advisors Israel II Ltd · director · last filing Aug 2023Orbimed Advisors LLC · director · last filing Aug 2023Orbimed Capital Gp Vii LLC · director · last filing Aug 2023Orbimed Genesis Gp LLC · director · last filing Aug 2023Orbimed Israel Gp II, L.P. · director · last filing Aug 2023Khuong Chau Quang · director · last filing Jun 2023Pedersen Anders · officer · last filing Jan 2023Lindmark Bertil · officer · last filing Jan 2023Oestreich Stephanie · officer · last filing Jan 2023Christgau Stephan · director · last filing Nov 2020Novo Holdings A/s · 10% owner · last filing Nov 2020Moller Soren · director · last filing Oct 2020
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.